Hysterectomy — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

A hysterectomy is the surgical removal of the uterus, permanently ending menstruation and the ability to carry a pregnancy. It is the second most common major gynaecological surgery performed in women (after caesarean section). The extent of surgery varies by indication and anatomy: total hysterectomy removes the uterine body and cervix; subtotal (supracervical) hysterectomy preserves the cervix; radical hysterectomy (Wertheim's) additionally removes the parametria and upper vagina for cervical cancer. Bilateral salpingo-oophorectomy (BSO) may be added to remove the ovaries and fallopian tubes — for cancer prevention in high-risk patients, or to treat ovarian disease simultaneously. Surgical approaches include laparoscopic hysterectomy (total laparoscopic hysterectomy, TLH — the preferred minimally invasive approach for most benign indications), vaginal hysterectomy (no abdominal incisions, preferred for uterine prolapse), robotic-assisted hysterectomy (available at specialist centres), and abdominal (open) hysterectomy (reserved for very large uteri, suspected malignancy with planned staging, or when minimally invasive approaches are contraindicated). Laparoscopic and vaginal approaches are associated with significantly faster recovery, less blood loss, and lower infection rates compared with open surgery.

This treatment represents an important component of modern medical management, supported by clinical evidence from multiple randomised controlled trials and systematic reviews. Treatment protocols are continually refined based on emerging evidence to optimise patient outcomes while minimising treatment burden.

Patient suitability is assessed through a structured multidisciplinary evaluation incorporating clinical history, physical examination findings, and results of relevant investigations. Treatment planning considers the full clinical context including disease characteristics, patient comorbidities, functional status, and individual treatment goals to ensure the most appropriate therapeutic approach is selected for each patient.

Hysterectomy is indicated for a range of benign and malignant gynaecological conditions that have either failed or are unsuitable for conservative management. Uterine fibroids (leiomyomata) causing significant heavy menstrual bleeding, pelvic pressure, urinary frequency, or bulk symptoms are the most common benign indication, particularly in women who have completed their family. Endometriosis with severe pelvic pain or adhesions refractory to hormonal therapy and laparoscopic excision may require hysterectomy with BSO. Adenomyosis causing severe dysmenorrhoea and heavy bleeding unresponsive to the Mirena IUS, GnRH agonists, and endometrial ablation. Endometrial cancer (most common gynaecological malignancy in developed countries) and cervical cancer require surgical staging via hysterectomy. Uterine prolapse causing symptomatic descent of the uterus into or beyond the vaginal introitus, particularly when vault suspension is indicated simultaneously. Refractory abnormal uterine bleeding not amenable to endometrial ablation or medical therapy. Persistent trophoblastic disease (gestational trophoblastic tumour) refractory to chemotherapy. Decision-making is individualised — fertility-sparing alternatives (myomectomy for fibroids, endometrial ablation for bleeding, uterine artery embolisation) are always considered first in women wishing to preserve fertility.

Laparoscopic total hysterectomy (TLH): Under general anaesthesia with urinary catheter and nasogastric tube, the abdomen is insufflated with CO2 gas and 3–5 ports (5–12 mm) are inserted. A uterine manipulator is placed transvaginally to mobilise the uterus. The round ligaments, fallopian tubes, utero-ovarian or infundibulo-pelvic ligaments, broad ligament peritoneum, uterine vessels, cardinal ligaments, and uterosacral ligaments are sequentially divided using advanced bipolar energy (LigaSure) or ultrasonic shears (Harmonic). The bladder is dissected free anteriorly. A colpotomy (circular cut at the cervico-vaginal junction) is made laparoscopically. The uterus (and cervix) are removed transvaginally. The vaginal vault is closed with absorbable sutures laparoscopically. BSO (if planned) is performed before uterine removal. Vaginal hysterectomy: No abdominal incisions — the uterus is delivered vaginally after ligation of the uterine pedicles from below. Abdominal (open) hysterectomy: A lower midline or Pfannenstiel (bikini-line) transverse incision provides direct access for large uteri (>16 weeks size), complex cases, or planned lymphadenectomy for cancer staging.

The procedure is performed in an appropriately equipped facility by experienced specialist clinicians. Prior to commencement, the patient undergoes pre-procedural assessment including vital signs measurement, review of relevant investigations, and confirmation of informed consent. Intravenous access is established and monitoring equipment including ECG, pulse oximetry, and blood pressure monitoring is applied.

The procedural site is prepared according to aseptic technique standards. Anaesthesia or analgesia is administered as appropriate for the specific procedure and patient needs, ranging from local anaesthesia for minor procedures to regional or general anaesthesia for more complex interventions.

The procedure is performed under direct visualisation or image guidance as appropriate. Key technical steps are executed with attention to anatomical landmarks and patient safety parameters. Haemostasis is achieved and confirmed before completion. Post-procedural assessment includes clinical evaluation of the immediate result, complication surveillance, and documentation of the procedure.

Recovery room monitoring continues until the patient meets defined discharge criteria. Written post-procedural instructions covering activity restrictions, wound care, medication management, and symptoms requiring urgent review are provided before discharge.

Hysterectomy provides definitive resolution of uterine-related symptoms in over 90% of patients. Randomised controlled trials (e.g., the VALUE study, STOP-Menorrhagia trial) demonstrate significant improvement in health-related quality of life, symptom scores, and patient satisfaction following hysterectomy compared with medical management for heavy menstrual bleeding. Laparoscopic hysterectomy has faster recovery (4–6 weeks versus 6–8 weeks for open), less blood loss (mean 250 mL versus 400 mL), lower wound infection rates, and equivalent oncological safety for benign disease. For endometrial cancer, total laparoscopic hysterectomy with bilateral salpingo-oophorectomy and lymph node sampling achieves equivalent 5-year survival to open staging (LAP2 trial — 5-year DSS 89.8% laparoscopic versus 88.8% open). Uterine fibroid-related symptoms are cured in 95–98% of patients. Adenomyosis symptoms resolve completely in nearly all patients after hysterectomy. Patient-reported satisfaction rates at 1 year exceed 90% for benign indications.

Urinary tract injury is the most common serious visceral complication: bladder injury during dissection occurs in approximately 0.5–1% and ureteric injury in 0.3–0.5%, both rates significantly higher with prior surgery or endometriosis. Intraoperative haemorrhage requiring transfusion affects 2–5% of cases. DVT and pulmonary embolism are prevented by preoperative risk stratification, thromboprophylaxis (LMWH), and compression stockings — continued for 28 days after hysterectomy for cancer. Vault dehiscence (separation of the vaginal cuff) is rare (0.2–0.5%) but requires prompt surgical closure. Vaginal vault granuloma presents at 6–12 weeks as abnormal discharge and is treated with topical silver nitrate cautery. Bowel injury is rare (<0.5%). Conversion from laparoscopic to open occurs in approximately 3% of cases for bleeding, poor visualisation, or adhesions. If BSO is performed before natural menopause, immediate surgical menopause causes significant vasomotor symptoms, urogenital atrophy, sexual dysfunction, accelerated bone loss, and potential cardiovascular risk — hormone replacement therapy (HRT) is recommended unless contraindicated (oestrogen-only HRT as the uterus is absent).

After laparoscopic hysterectomy, hospital discharge occurs within 24–48 hours with oral analgesia. The urinary catheter is removed within 24 hours. Light activity and walking are encouraged from day 1. Patients should avoid heavy lifting over 5 kg for 6 weeks, sexual intercourse for 6–8 weeks (until vaginal cuff healing is confirmed), and driving for 4–6 weeks (or until sudden braking can be performed comfortably). Return to desk work is typically 3–4 weeks; manual work 6–8 weeks. Open hysterectomy requires 3–5 days hospital stay and 6–8 weeks full recovery. Post-operative oestrogen-only HRT is recommended for pre-menopausal women who have had BSO, commenced within 1–2 weeks of surgery to prevent acute menopausal symptoms and protect bone density and cardiovascular function. Follow-up is typically at 6 weeks for clinical review, wound assessment, and vaginal vault examination. Cervical smear tests are no longer required after total hysterectomy (cervix removed) for benign indications. Pelvic floor physiotherapy is recommended from 8 weeks to reduce urinary symptoms and vault prolapse risk.